-
2024-511631-10-00
9
2023-02-27
Hodgkin’s lymphoma
-
2024-517942-33-03
5
2023-02-04
cardiac amyloidosis
-
2024-520119-41-00
4
2023-01-15
Previously untreated patients with diagnosis of HCL
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2023-507883-38-00
5
2019-11-18
Systemic Juvenile Idiopathic Arthritis
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-514942-35-00
3
2025-04-11
Type 1 interferonopathies
-
2023-508055-40-00
6
2025-02-18
Obesity
-
2024-518669-83-00
4
2024-12-05
acute promyelocytic leukemia (APL) in children and adolescents
-
2024-518531-10-00
4
2024-11-26
Phase II, open label, multicentric, proof-of-principle basket trial in
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2024-512676-36-00
10
2024-10-09
Langerhans Cell Histiocytosis
-
2022-502238-22-00
5
2024-05-14
Ulcerative Colitis
-
2023-506669-70-00
5
2024-04-30
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
-
2023-506735-15-00
5
2024-04-05
Erythropoietic Protoporphyria or X-Linked Protoporphyria
-
2022-501176-26-00
5
2023-08-04
Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H